Docj I tried to sell a few on TDA my shares are restricted for some reason. I received them from last years dividend. Do you know anything. Thanks in advance.

Nugenerex Immuno Oncology Inc Common Stock (PC) OTC BBN NUGX
$3.00 up 2.90 up (2,900.00%)

Not Bad :)

Nugenerex Immuno Oncology Inc Common Stock (PC) OTC BBN NUGX
$3.00 up 2.90 (2,900.00%)

Hey Mike got tired of the BS besides a few people here-there. I also think Gold Miner stocks look attractive currently. Like BTG and others. Still own a portion of QTMM

Graphite is the new gold. The upside for Canada's Largest Refined Graphite Preserve in North America will be critical for Battery Storage and EV Batteries. Note: 50% is Graphite (Anode) along with other precious metals. NMG has cleared many hurtles and soon to be full scale operation. Buy It and don't sell. Its early.

https://nouveaumonde.group/about-us/

$NMGRF is the freaking real deal The upside for Canada's Largest Refined Graphite Preserve in North America will be critical for Battery Storage and EV Batteries. Note: 50% is Graphite (Anode) along with other precious metals. NMG has cleared many hurtles and soon to be full scale operation. Buy It and don't sell. Rising Tide

https://nouveaumonde.group/about-us/

Thank me later https://stocktwits.com/symbol/NMGRF

See ya in 2025

Up on my Roth IRA took 5 years :)

Yes, Nice Trunaround

Train leaving the station. Woot Woot

2016 2020 2020 The American people should have a voice in the selection of their next Supreme Court Justice. Therefore, this vacancy should not be filled until we have a new president. - Mitch McConnell in FEBRUARY 2016

MOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOORE Fromm Escuchará a los HSH decir que los llamé violadores, que todos eran miembros de la MS-13, que están invadiendo nuestro país en caravanas y que encerré a sus hijos en la frontera, ¡no es cierto!Como nunca dije, el virus era peligroso, altamente contagioso y cinco veces más mortal que la gripe

You'll hear the MSM say I called you rapists, that you were all members of MS-13, that you're invading our country in caravans, and that I locked your children up at the border - not true!

Just like I never said the virus was dangerous, highly contagious, and five times more deadly than the flu...

Hello NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNo His latest insinuation is I am the only one who can preserve "law and order" trying to scare people into voting for him otherwise "the suburbs will be inundated with black and brown poor people" this is a very racist and stereotyping people of color.

QDX HealthID Signs Distribution Agreement with Innova Medical Group Inc. Adding Antigen, Molecular and Antibody Tests to its COVID-19 Test Ecosystem

QDX™ HealthID’s ecosystem now includes 6 of 12 FDA Emergency Use Authorized
rapid result COVID-19 tests

San Marcos, Texas, and Monrovia, Calif, Aug. 12, 2020 (GLOBE NEWSWIRE) -- QDX HealthID Incorporated, a wholly owned subsidiary of Quantum Materials Corp. (OTC Bulletin Board: QTMM) – today announced that, in conjunction with its parent, has signed a distribution agreement with Innova Medical Group Inc. (IMG), a wholly owned subsidiary of Pasaca Capital, Inc., for the inclusion of IMG’s rapid-result antigen and antibody tests, and PCR swab tests, in the QDX™ HealthID ecosystem of COVID-19 testing solutions.

QDX™ HealthID, currently in beta release, is a SaaS-based platform allowing companies and individuals to view and select a particular COVID-19 test kit, authenticate and record their test results in a secure way, and then share authenticated results with friends, family—or any other third party to share negative virus statuses.

With this agreement, the QDX™ HealthID test kit ecosystem now includes 6 out of 12 rapid-result antibody tests currently granted the Food & Drug Administration’s (FDA) Emergency Use Authorization (EUA). These test kits, and same-day antigen tests may be performed at point-of-care facilities and best support the most effective COVID-19 testing strategies that eliminate delays in receiving test results, which often render testing and tracking efforts completely ineffective.

The agreement between QDX™ HealthID and IMG allows users registered on the QDX™ HealthID platform to use an IMG-supplied test kit — when a healthcare provider prescribes it. The agreement is non-exclusive and allows other registered test kits and diagnostic services to be used by QDX™ HealthID customers.

Innova Medical Group Inc. (IMG) is a wholly owned subsidiary of Pasaca Capital. It brings the most innovative medical technologies to the global market to benefit as many people as possible. Pasaca Capital Inc. and Innova Medical Group Inc. were founded by Dr. Charles Huang.

"We are excited to be working with Innova Medical Group and adding its test kit portfolio to our QDX™ HealthID ecosystem," says Stephen B. Squires, CEO of QDX HealthID Incorporated. "This ecosystem now offers a comprehensive set of COVID-19 testing options allowing QDX™ HealthID to address the health safety needs of myriad industries and testing environments."

“We are confident that adding QDX HealthID Incorporated to Innova Medical Group’s rapid test kit distribution group will ensure that even more, superior testing solutions will continue being a key solution for effectively detecting and tracking the COVID-19 virus, worldwide,” shares Dr. Charles Huang, Founder and Partner of Pasaca Capital Inc. “As industry leaders specializing in research, development, and the production of point-of-care testing, in-vitro diagnostic devices, and reagents, our test kit developers are all well-known as makers of superior technologies providing better healthcare solutions to benefit people everywhere.”

YOOOOOOOOOOOOOuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuu

Desperate Trump cannot run on the economy as planned, He failed on the Coronavirus which is surging and probably going to send the USA into a Depression. He Praises Putin who put a Bounty on US Troops. He is sending Troops to Attack Americans. This man is NOT A LEADER Nope

gogogogogogogoggoogogoggggooooooooooooooooooogggg More insights

Trump cannot run on the economy as planned, He failed on the Coronavirus which is surging and probably going to send the USA into a Depression. He Praises Putin who put a Bounty on US Troops. He is sending Troops to Attack Americans. This man is NOT A LEADER and SHOULD BE VOTED OUT!!

From TDA 6/23/20 I can understand your concern regarding your shares of MISTRAL VENTURES INC. I have contacted our Corporate Actions Department regarding the reverse split and name change to NDT Pharmaceuticals and they stated we have not receive the new shares from the companies. We also have not received an anticipated swing date from them when they expect to deliver the reorganized shares. Once we do get the new shares from the companies we will post them to your account.

If you have any further questions regarding this reorganization you may speak to our Corporate Actions department directly at 888-723-8504 Ext. 1 Monday through Friday from 8:00 AM to 4:30 PM CST. If there is anything else I can do for you please do not hesitate to reply. Your business is appreciated, and I want to make sure I address all your questions and concerns.

EBS Partnerships Shares of Emergent BioSolutions Inc. (EBS) announced a five-year deal with Johnson & Johnson (JNJ) to manufacture the drug substance for the drugmaker's still-investigational COVID-19 vaccine. J&J will pay $480 million for two years of Emergent's contract development and manufacturing services. The two companies had previously announced in April (http://www.marketwatch.com/story/jj-to-pay-emergent-135-million-as-part-of-covid-19-vaccine-manufacturing-deal-2020-04-24) a deal to reserve manufacturing capacity for J&J's vaccine candidate. Emergent has also announced coronavirus vaccine manufacturing deals with AstraZeneca (AZN.LN), Novavax (NVAX) and Vaxart Inc. (VXRT) as part of a new strategy (http://www.marketwatch.com/story/race-for-a-covid-19-vaccine-has-drug-makers-scaling-up-manufacturing-before-one-is-developed-2020-06-25) to build out manufacturing capacity for COVID-19 vaccines before they have proven their efficacy or safety.

https://ih.advfn.com/stock-market/NYSE/emergent-biosolutions-EBS/stock-price

Corrently speaking of the corona virus and what is not being done

of stopping federal funding of COVID-19 testing in the middle of the pandemic
of trying to deprive 23 million Americans of health care
of corrupting the Department of Justice
of lowering the status of America internationally
of cozying up to dictators while insulting allies which are democracies
of destroying the farmers of America
of insulting minorities, whether Black, Hispanic or Asian
of depriving America of needed IT engineers
of increasing the price of goods through tariffs paid by Americans (not by Chinese)
of disregarding the Constitution with impunity
of disregarding Congress with impunity
of generally destroying America to save himself.

QTMM up today, Have a great weekend all.

Not posting or caring what happens on I-Hub and the QTMM Board. I will stay as a Moderator and post when India, Anti-counterfeiting, Displays, Health ID is up and successful. Have fun in the meantime, the I-Box is all yours.

I will check in when QMC is successful and have the last laugh

Stop, Sticky is enough

Where is this being traded? My TDA Account 60649M300 invalid symbol however it does show NDTP

[img][/img]

Interesting news for sure. 8K https://ih.advfn.com/stock-market/USOTC/generex-biotechnology-qb-GNBT/stock-news/82642213/current-report-filing-8-k

Went up to 45 cents bro..

Things are far from over. Just delays due to corona virus. Still think their best bet is QD Anti-counterfeiting and India,

Yep, MBS REITS and value oriented stocks are real buys trading below book value.

What a complete waste of time.

Stock went up like my entire value portfolio :)

I understand that, my current portfolio understands that.

Good looking forward to that, I can wait this out QT.

QMC will have their day and I will sell some of my margin and buy lots of shares. That day has not arrived yet however it will, just like the beginning of a new dawn. In the meantime have fun knocking Squires and you use of distasteful language.

Keep driving the s/p down when QMC is finally successful I have $$$ waiting.

The I-Box is the only thing worth reading.

QDX Health, https://www.quantummaterialscorp.com/

Give em hell Dx :)

Generex Subsidiary NGIO Advances COVID-19 Vaccine Program with the Manufacturing of Patent-Pending Ii-Key-SARS-CoV-2 Peptides

NuGenerex Immuno-Oncology (NGIO) is focused on modulation of the immune system to develop Ii-Key peptide vaccines for the treatment and prevention of cancer and infectious diseases
NGIO advancing Ii-Key peptide vaccines against the SARS-CoV-19 pandemic
Ii-Key Peptides Advancing to Clinical Laboratory “Ex-Vivo” Human Immune System Screening Program
NGIO’s AE37 Phase II breast cancer trial peer review data just published showing significantly positive results at 10 years with additional benefit to late stage patients https://storage.googleapis.com/wzukusers/user-26831283/documents/c8e4b2bab3d647968f576008791340f3/Brown2020_Article_ProspectiveRandomizedSingle-bl.pdf

MIRAMAR, Fla., May 22, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that their COVID-19 vaccine program has reached a milestone with the manufacturing of 33 Ii-Key-SARS-CoV-2 peptides using antigenic epitopes predicted by computational vaccinology algorithms. Provisional patent applications have been filed for these Ii-Key-SARS-2 peptides, protecting intellectual property rights for Generex and COVID-19 vaccine products based on the viral sequences with Ii-Key. Once the peptides pass Quality Assurance testing, they will be shipped to the clinical laboratories conducting the “Ex-Vivo” Human Immune System Screening Program using blood and plasma samples from patients who have recovered from COVID-19 that have already been collected and stored for the screening program. The unique ex-vivo human immune system studies with convalescent blood samples will provide the data to select the best Ii-Key-SARS-CoV-2 peptides for a “Complete Vaccine” that promotes B-Cell production of neutralizing antibodies and activates CD4+ T-Cell responses (TH1) that promote immune memory and potential long-term protection from coronavirus infection. Additionally, the vaccine screening program will address the safety of the Ii-Key-SARS-CoV-2 peptides using a validated in-vitro assay that models the dangerous cytokine storm associated with COVID-19.

Joseph Moscato, Generex President & CEO, stated, “We are excited to continue advancing the COVID-19 vaccine program, taking another step to unlocking the value and true potential of our immuno-oncology assets. Not only are we moving ahead with our coronavirus vaccine program, but we are also achieving milestones in our oncology program, as demonstrated by the recently published results of the Phase IIb clinical trial of the Ii-Key-HER2 peptide vaccine AE37 for the prevention of recurrent breast cancer. The trial demonstrated that patients with advanced breast cancer and low levels of HER2/neu who were treated with AE37 immunotherapy had a statistically significant improvement in disease free survival over 10 years.

“The statistically significant and positive AE37 clinical trial results validate our continued work with the National Surgical Adjuvant Bowel & Breast Project (NSABP) to develop AE37 in combination with pembrolizumab (Merck’s Keytruda®) for the immunotherapeutic treatment of triple negative breast cancer. Trial enrollment was slowed recently due to the coronavirus, but we are expanding enrollment efforts, and we have added the world-famous Cleveland Clinic as one of our NSABP sites. We expect enrollment to speed up with these positive results as the coronavirus pandemic subsides. Also, in the next quarter we are planning to initiate a trial of AE37 in combination with checkpoint inhibitor for the immunotherapeutic treatment of bladder cancer with investigators at MD Anderson Cancer Center, and we have begun to plan a trial of the Ii-Key-GP100-TYR peptide vaccine for the treatment of melanoma.”

Mr. Moscato continued, “Over the last two months, Generex has responded to the COVID-19 emergency using our technology platform to work to develop an Ii-Key-SARS-CoV-2 vaccine. We have licensed coronavirus epitope sequences and we are in the process of manufacturing Ii-Key peptides that will be screened against blood samples from patients who recovered from COVID-19 in an “Ex-Vivo” human study. We have established a plan to test the Ii-Key peptides in a complete immunology screening program to evaluate their ability to modulate CD4+ and CD8+ T-Cell responses. Additionally, we will select peptides based on their ability to bind neutralizing antibodies that provide immunity to the virus. We will be testing the antibodies in virus neutralization assays to select the peptides for the vaccine, and in a cellular assay that models the cytokine storm in order to eliminate peptides that may cause an adverse immunologic response. With the results from our broad and proprietary immunological screening program, which we anticipate having in June, we will have an early indication of the immunologic efficacy and safety of an Ii-Key-SARS-CoV-2 peptide vaccine before our clinical trials even start. These Ex-Vivo human immune system studies are designed to enable the development of a “Complete Vaccine” to provide immunity from COVID-19 without the cytokine storm potential that is so worrisome for coronavirus vaccines developed with whole virus, recombinant protein vaccines, and nucleic acid vaccines that do not have the specificity of Ii-Key peptide vaccines.”

In the coming weeks Generex will be announcing a shareholder’s conference call to give a complete operations update.

http://www.globenewswire.com/news-release/2020/05/22/2037654/0/en/Generex-Subsidiary-NGIO-Advances-COVID-19-Vaccine-Program-with-the-Manufacturing-of-Patent-Pending-Ii-Key-SARS-CoV-2-Peptides.html

This is a STARTUP remember

Really, sorry to inform delays happen.